Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy Meeting Abstract
| Authors: | Escudier, B. J.; Porta, C.; Squires, M.; Szczylik, C.; Kollmannsberger, C. K.; Melichar, B.; Rha, S. Y.; Esteban, E.; Bjarnason, G. A.; Vogelzang, N. J.; Sternberg, C. N.; Shi, M.; Marker, M.; Motzer, R. J. |
| Abstract Title: | Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy |
| Meeting Title: | 2014 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2014 Jan 30-Feb 1 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-02-01 |
| Language: | English |
| ACCESSION: | WOS:000335318100471 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.4_suppl.473 |
| Notes: | Meeting Abstract: 473 -- Genitourinary Cancers Symposium -- JAN 30-FEB 01, 2014 -- San Francisco, CA -- S -- Source: Wos |
